BACKGROUND: The nuclear factor-κB pathway is an important signaling pathway activated in multiple myeloma cells. Bortezomib inhibits nuclear factor-κB activation and is an important antimyeloma agent. Nevertheless, patients treated with this drug eventually relapse. We hypothesized that the nuclear factor-κB pathway may be associated with multiple myeloma and patients' responses to bortezomib. DESIGN AND METHODS: In this study we analyzed 26 polymorphism sites of nuclear factor-κB family member genes, IKBα, NFKB2, and TRAF3, in 527 unrelated Chinese Han subjects (252 with multiple myeloma and 275 controls) using a Sequenom MassARRAY genotyping assay, and examined the outcome of 83 patients treated with a bortezomib-based regimen. RESULTS: Single nucleotide polymorphisms in the TRAF3 rs12147254 A allele and a specific haplotype 1 of TRAF3 [GAACAG] are associated with a decreased risk of multiple myeloma (odds ratio 0.709, P<0.001, and odds ratio 0.543, P<0.0001), while TRAF3 haplotype 4 [GGACAG] was associated with an increased risk of development of multiple myeloma (odds ratio 2.099, P=0.001). Moreover, the TRAF3 rs11160707 GA+AA genotype was significantly associated with a better progression-free survival (P=0.018). Patients with the NFKB2 rs12769316 GA+AA genotype had a superior overall survival (P=0.020), while those with the rs1056890 CT+TT genotype had an inferior overall survival (P=0.037). In an exploratory analysis, patients with the GA+AA/CC/GG genotype at the rs12769316, rs1056890, and rs11160707 sites had a significantly superior overall survival compared to patients with a wild-type genotype (P=0.007). In the multivariable analysis, TRAF3 rs11160707 was found to be an independent favorable factor for progression-free survival (hazard ratio 0.428, P=0.028). CONCLUSIONS: Nuclear factor-κB family member gene polymorphisms play a role in the development of multiple myeloma and in the response to bortezomib therapy.
BACKGROUND: The nuclear factor-κB pathway is an important signaling pathway activated in multiple myeloma cells. Bortezomib inhibits nuclear factor-κB activation and is an important antimyeloma agent. Nevertheless, patients treated with this drug eventually relapse. We hypothesized that the nuclear factor-κB pathway may be associated with multiple myeloma and patients' responses to bortezomib. DESIGN AND METHODS: In this study we analyzed 26 polymorphism sites of nuclear factor-κB family member genes, IKBα, NFKB2, and TRAF3, in 527 unrelated Chinese Han subjects (252 with multiple myeloma and 275 controls) using a Sequenom MassARRAY genotyping assay, and examined the outcome of 83 patients treated with a bortezomib-based regimen. RESULTS: Single nucleotide polymorphisms in the TRAF3rs12147254 A allele and a specific haplotype 1 of TRAF3 [GAACAG] are associated with a decreased risk of multiple myeloma (odds ratio 0.709, P<0.001, and odds ratio 0.543, P<0.0001), while TRAF3 haplotype 4 [GGACAG] was associated with an increased risk of development of multiple myeloma (odds ratio 2.099, P=0.001). Moreover, the TRAF3rs11160707 GA+AA genotype was significantly associated with a better progression-free survival (P=0.018). Patients with the NFKB2rs12769316 GA+AA genotype had a superior overall survival (P=0.020), while those with the rs1056890 CT+TT genotype had an inferior overall survival (P=0.037). In an exploratory analysis, patients with the GA+AA/CC/GG genotype at the rs12769316, rs1056890, and rs11160707 sites had a significantly superior overall survival compared to patients with a wild-type genotype (P=0.007). In the multivariable analysis, TRAF3rs11160707 was found to be an independent favorable factor for progression-free survival (hazard ratio 0.428, P=0.028). CONCLUSIONS: Nuclear factor-κB family member gene polymorphisms play a role in the development of multiple myeloma and in the response to bortezomib therapy.
Authors: A Abdallah; H Sato; J C Grutters; S Veeraraghavan; P A Lympany; H J T Ruven; J M M van den Bosch; A U Wells; R M du Bois; K I Welsh Journal: Genes Immun Date: 2003-09 Impact factor: 2.676
Authors: Wolfram Klein; Andreas Tromm; Christian Folwaczny; Michaela Hagedorn; Natascha Duerig; Joerg T Epplen; Wolff H Schmiegel; Thomas Griga Journal: Int J Colorectal Dis Date: 2003-09-13 Impact factor: 2.571
Authors: Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson Journal: N Engl J Med Date: 2003-06-26 Impact factor: 91.245
Authors: J Bladé; D Samson; D Reece; J Apperley; B Björkstrand; G Gahrton; M Gertz; S Giralt; S Jagannath; D Vesole Journal: Br J Haematol Date: 1998-09 Impact factor: 6.998
Authors: Sophia P Karabela; Ioannis Psallidas; Taylor P Sherrill; Chrysoula A Kairi; Rinat Zaynagetdinov; Dong-Sheng Cheng; Spyridoula Vassiliou; Frank McMahon; Linda A Gleaves; Wei Han; Ioannis Stathopoulos; Spyros G Zakynthinos; Fiona E Yull; Charis Roussos; Ioannis Kalomenidis; Timothy S Blackwell; Georgios T Stathopoulos Journal: Carcinogenesis Date: 2012-01-27 Impact factor: 4.944
Authors: Geraldine Leung; Christina Baggott; Claudia West; Charles Elboim; Steven M Paul; Bruce A Cooper; Gary Abrams; Anand Dhruva; Brian L Schmidt; Kord Kober; John D Merriman; Heather Leutwyler; John Neuhaus; Dale Langford; Betty J Smoot; Bradley E Aouizerat; Christine Miaskowski Journal: Lymphat Res Biol Date: 2014-02-06 Impact factor: 2.589
Authors: Eeeseung Byun; Caryl L Gay; Carmen J Portillo; Clive R Pullinger; Bradley E Aouizerat; Kathryn A Lee Journal: Sleep Med Date: 2017-01-20 Impact factor: 3.492
Authors: Christine Miaskowski; Yvette P Conley; Judy Mastick; Steven M Paul; Bruce A Cooper; Jon D Levine; Mitchell Knisely; Kord M Kober Journal: J Pain Symptom Manage Date: 2017-08-08 Impact factor: 3.612
Authors: Nicole A Lavender; Erica N Rogers; Susan Yeyeodu; James Rudd; Ting Hu; Jie Zhang; Guy N Brock; Kevin S Kimbro; Jason H Moore; David W Hein; La Creis R Kidd Journal: BMC Med Genomics Date: 2012-04-30 Impact factor: 3.063